With Clontech on the Block, BD Biosciences to Focus on Cellular Analysis | GenomeWeb

Does the new biology lie in the area of cellular analysis?

BD Biosciences, the approximately $600 million unit of Becton Dickinson, certainly seems to think so. Last week, when the company announced plans to sell its Clontech business, it told the market it intends to fully shift its attention to cellular analysis and drug-discovery technologies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.